Monocyte adhesion to subendothelial components

Human monocytes have been shown to penetrate the endothelial layer of large blood vessels and to adhere to the subendothelial basement membrane. To determine the active components of this process, we have studied the ability of monocytes to adhere to isolated components of the subendothelial matrix. Using a quantitative dot-blot adhesion assay, we find that monocytes adhere preferentially to immobilized laminin and elastin. The monocytes adhere less well to fibronectin and bind poorly or not at all to collagen types I and IV, or to heparan sulfate. Monocyte binding to elastin requires an intact, crosslinked molecule as no binding was observed to soluble, acid-alcohol elastin extracts, to pepsin or elastase digests of elastin, to tropoelastin monomer, or to desmosine/isodesmosine crosslinks. Similar binding profiles to elastin, laminin, and fibronectin were seen with the established human leukocyte cell line U937. The promyelocytic cell line HL60 adhered equally well to laminin but showed slightly reduced adhesion to elastin when compared with the fresh monocytes or U937 cells. Freshly isolated human erythrocytes did not demonstrate significant adhesion to fibronectin, laminin, or elastin.     

防御素的抗肿瘤研究

当代肿瘤的治疗仍有许多问题未能解决防御素引入肿瘤墓因治疗已成为一个有前景的新途径.防御素(defensins)是存在于哺乳动物多形核中性粒细胞、巨噬细胞、小肠Peneth细胞中的一组同源性很高的生物多肤类,由29一34     

Strengthen international academic exchange and promote development of gastroenterology

ＳｔｒｅｎｇｔｈｅｎｉｎｔｅｒｎａｔｉｏｎａｌａｃａｄｅｍｉｃｅｘｃｈａｎｇｅａｎｄｐｒｏｍｏｔｅｄｅｖｅｌｏｐｍｅｎｔｏｆｇａｓｔｒｏｅｎｔｅｒｏｌｏｇｙＭＡＬｉａｎＳｈｅｎｇａｎｄＰＡＮＢｏＲｏｎｇＡｐｐｒｏｖｅｄｂｙｔｈｅＣｈｉｎａｓｔａｔ...     

Improving outcomes for high-risk DLBCL: a pilot study looking at the role of fractionated cyclophosphamide with RCHOP chemo-immunotherapy (SCUBA-1 trial)

The outcomes for patients with high-risk DLBCL are suboptimal, especially in Low-middle income countries in comparison to published data from the western world. Most newer therapies aimed at improving outcomes are either unavailable or out of reach for the majority of patients in low-middle income countries. Cyclophosphamide is an easily available and accessible drug that forms the backbone for therapy for DLBCL. We conducted a single-center, open-label randomized pilot study comparing standard RCHOP to RCHOP with fractionated cyclophosphamide (RfCHOP) in patients with newly diagnosed, high-risk DLBCL. Fifty-five patients were randomized- 28 to RfCHOP and 27 to the RCHOP arm. RfCHOP was associated with a higher complete response rate than RCHOP at the end of 6 cycles of therapy (81.2% vs. 59.3%; p-0.062). Grade III/IV adverse events were comparable in both arms with the use of prophylactic GCSF in the RfCHOP arm. At a median follow-up of 22 months, the Median EFS and OS was not reached in either arm. RfCHOP may represent a therapeutic option for patients with newly-diagnosed, high-risk DLBCL, especially in Low-middle income countries. Larger studies are required to confirm these findings.